Eli Lilly licenses Adimab antibody discovery and optimization tech

Adimab, LLC is transferring its proprietary antibody discovery and optimization platform to Lilly research sites in San Diego and New York.

Filed under: R&D

Add-on azithromycin cuts asthma exacerbations

FROM THE LANCET Adults with persistent symptomatic asthma who took azithromycin as an add-on therapy experienced fewer exacerbations and had …

Filed under: Respiratory

Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry and early lead development.

Filed under: Inflammatory

5 trends shaping Alzheimer’s drug development

Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned.

Filed under: Alzheimer’s

FDA panel backs Novartis’ CAR-T therapy CTL019

Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel.

Filed under: Cancer, Immunotherapy

Sanofi to Acquire Protein Sciences

NewsAcquisition adds recombinant-based influenza vaccine to Sanofi Pasteur’s portfolio.Contributed Author: SanofiTopics: Pharma Mergers & Acquistions

Filed under: Company

Perspectives: More Transparent Pricing System Would Help Untangle Confusion Around High Costs

Read recent commentaries about drug-cost issues.

Filed under: Pricing

Trovagene Announces Agreement with Novogene for NextCollect™ in China

SAN DIEGO, July 12, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequ…

Filed under: Emerging Markets

Alnylam Buckles Down On A Belt Of Rare Diseases

Filed under: Company

Celgene joins PD-1 race via partnership with BeiGene

The pharma giant will pay the Chinese firm up to $980m in milestone payments

Filed under: Cancer, Immunotherapy

Novartis’ psoriasis drug gets label boost

New label shows Cosentyx is superior to J&J’s rival in long-term.
The post Novartis’ psoriasis drug gets label boost appeared first on Pharmaphorum.

Filed under: Inflammatory

NICE recommends AstraZeneca lung treatment

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) is has emerged, meaning the therapy could soon be available for routine use on the NHS. The assessment covers adults whose severe COPD has not responded to other treatments.
read more

Filed under: COPD

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be used on the NHS for the treatment of severe active forms of the disease which has not responded to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs), it has emerged.
read more

Filed under: Arthritis

Roche acquires mySugr to form a leading open platform for digital diabetes management

Roche and mySugr announced today that the two partners have signed an agreement under which Roche acquired all shares of mySugr GmbH.

Filed under: Diabetes

Regulation of orphan drugs within the EU

Filed under: General

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents

Merck’s CETP inhibitor anacetrapib and Novartis’ monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.

Filed under: Cardiovascular

AstraZeneca at Cannes: Healthcare delivery’s speeding away from pharma’s marketing model

Can smartphones upend commerce in biopharma? AstraZeneca thinks they might, which is why the U.K.-based drug giant teamed up with Babylon Health in an artificial intelligence pilot project that’s more healthcare than pharma.

Filed under: Marketing

Op-Ed: Why single-payer health-care could be closer than you think

How chaos surrounding the GOP’s health-care plan could bring the U.S. closer to single-payer, says Proteus Duxbury.

Filed under: Payer

EU tests limits of drug pricing freedom in landmark probe

BRUSSELS/LONDON (Reuters) – The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.

Filed under: Pricing

Biosimilar immunogenicity studies produce no surprises

MADRID (FRONTLINE MEDICAL NEWS) – Two biosimilar tumor necrosis factor inhibitor (TNFi) products are no more immunogenic than their reference biologic counterparts in patients with rheumatoid arthritis (RA), according to the results of two studies presented at the European Congress of Rheumatology. Results of one study, which involved 544 RA patients, showed 33.1% treated with […]

Filed under: Biosimilar